Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will evaluate Zydis Technology to develop thermo stable and cold-chain independent vaccines
April 21, 2015
By: Kristin Brooks
Managing Editor, Contract Pharma
Catalent has received a project grant as part of a consortium looking to develop and manufacture thermo stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Currently, 90% of existing vaccines are cold-chain dependent, and the goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent. A total project fund of €5.3 million has been awarded as part of Horizon 2020, the EU research and innovation framework program, with additional funding of as much as €3.1 million from the Swiss State Secretariat Education, Research and Innovation (SERI) for the Swiss based consortium partners. The MACIVIVA project, which stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines” will run 3.5 years and brings together global expertise in the field of virosome vaccines, manufacturing, spray drying, freeze drying and analytical techniques from the pharma industry. Catalent’s Swindon, UK facility, the manufacturing hub of its Zydis fast-dissolve formulation technology, will receive a portion of the total fund along with other consortium partners: Mymetics SA (Switzerland), Mymetics BV (Netherlands); Chimera Biotech Gmbh (Germany); Upperton Ltd. (UK); and Bachem AG (Switzerland). “Catalent is pleased to be part of this consortium of cross-industry partners bringing innovative technologies together to address a serious global issue in the over-reliance on the cold chain with existing vaccines,”said Barry Littlejohns, Catalent’s president of Advanced Delivery Technologies. “Zydis is the world’s best-in-class, orally disintegrating tablet technology, and we believe our experience and expertise in this area can add substantially to the project as a whole. Because of the supply chain constraints, large populations are denied access to vaccines, so we, as a group, recognize the importance and potential of this work for global vaccine development.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !